GPCR (structuretx.com) Rasio Nilai Pasar marang Nilai Buku

Simbol resmi perusahaan Structure Therapeutics Inc (GPCR)

Structure Therapeutics (GPCR) minimizes capital expenditures by outsourcing formula development and testing to external contractors. Thanks to its unique oral solutions, the startup is positioning itself for a significant niche in the weight loss segment, avoiding price wars. Revenue is based on the market launch of innovative diabetes pills, where the metric stands at 1.10. Serving as a valuation tool, this price chart clearly visualizes the dynamics of this asset.

GPCR Structure Corp: Nilai Pasar marang Nilai Buku ing interval 28.04.2023 - 27.10.2026

Rincian metrik keuangan lan pasar Structure Therapeutics Inc (GPCR)

- rega lan prakiraan konsensus rega:
Bagan rega Structure Therapeutics|GPCR - Konsensus nilai wajar
- data kapitalisasi pasar:
Nilai pasar Structure Pharma|GPCR - Nilai Wutuh Bisnis
- data kapitalisasi buku:
Nilai Buku saben Saham Structure Therapeutics|GPCR - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku structuretx.com|GPCR - Total Aset Perusahaan
- data utang lan likuiditas:
Utang marang Ekuitas Structure Therapeutics|GPCR - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Structure Pharma|GPCR - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Structure Pharma
Analisis wiwitan perusahaan:Structure Therapeutics - GPCR
Produk asli Structure Pharma

This ratio determines the market value premium over net assets, separating the objective value of the balance sheet from the subjective expectations of investors. By analyzing the relationship between the market valuation of Structure Therapeutics (GPCR) and its book value, it becomes evident that the high valuation of Structure Therapeutics (GPCR) is driven not by current resources, but by the potential for future clinical success in the development of metabolic drugs amid low cash flow predictability.

Pesaing utama

Rasio Nilai Pasar marang Nilai Buku Ascendis Pharma A/S ASND|MDGL (madrigalpharma.com) - Nilai Pasar marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku Corcept Therapeutics Incorporated CORT|Kapitalisasi Pasar marang Aset Bersih Rhythm Pharma|Akero Therapeutics Inc (AKRO) - Rasio Kapitalisasi Pasar marang Nilai Buku|Nilai Pasar marang Nilai Buku Metsera Therapeutics (MTSR)|Rasio Kapitalisasi Pasar marang Nilai Buku MLTX (MoonLake Immunotherapeutics)|crinetics.com - Rasio Kapitalisasi Pasar marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku NewAmsterdam Pharma Company N.V. (NAMS)|SLNO: Nilai Pasar marang Nilai Buku|FOLD (Amicus Pharma) - Rasio Nilai Pasar marang Nilai Buku|89bio Pharma (ETNB) - Rasio Kapitalisasi marang Aset Bersih|AGIO (Agios Pharmaceuticals) - Rasio Kapitalisasi Pasar marang Nilai Buku|Rasio Kapitalisasi Pasar marang Nilai Buku mimedx.com (MDXG)|Rezolute (RZLT) - Rasio Kapitalisasi marang Aset Bersih|Nilai Pasar marang Nilai Buku LXRX (Lexicon Pharmaceuticals Inc)|MBX Bio - Rasio Nilai Pasar marang Nilai Buku|Rasio Kapitalisasi marang Aset Bersih Altimmune Pharma ALT|AARD (Aardvark Therapeutics Inc) - Rasio Kapitalisasi Pasar marang Nilai Buku|sagimet.com (SGMT) - Koefisien Nilai Pasar marang Nilai Buku|BIOA - Rasio Kapitalisasi marang Aset Bersih|Biomea Fusion Inc (BMEA) - Multiplikator Kapitalisasi Pasar marang Nilai Buku|QNCX (Quince Therapeutics Inc) - Rasio Kapitalisasi Pasar marang Nilai Buku|Rasio Kapitalisasi Pasar marang Nilai Buku Fractyl Health, Inc|Rasio Kapitalisasi Pasar marang Nilai Buku vTv Therapeutics Inc. (VTVT)|Rasio Nilai Pasar marang Nilai Buku ATPC (agapeatpgroup.com)|PLUR: Rasio Nilai Pasar marang Nilai Buku|Synlogic Inc. - Koefisien Nilai Pasar marang Nilai Buku|LPCN - Rasio Nilai Pasar marang Nilai Buku|MTNB - Rasio Nilai Pasar marang Nilai Buku|Spruce Biosciences - Rasio Kapitalisasi Pasar marang Nilai Buku|GLTO (galecto.com) - Kapitalisasi Pasar marang Nilai Buku|CTCX: Rasio Nilai Pasar marang Nilai Buku|Kapitalisasi Pasar marang Nilai Buku LUMO|Rasio Nilai Pasar marang Nilai Buku ONVO (Organovo Holdings Inc)|Rasio Kapitalisasi marang Aset Bersih RDUS (Radius Pharmaceuticals)